MS4A1 and mantle cell lymphoma: In fact, splenic MZL is often treated with non-aggressive regimens including [15,16], while therapy of MCL involves more aggressive regimens, such as hyper-cyclophosphamide, vincristine, Adriamycin (doxorubicin) and dexamethasone (CVAD) or FCM, possibly associated with anti-CD20 MoAb [17].